ICON (NASDAQ:ICLR) stock fell 8% early Tuesday after it issued financial guidance for 2025. The clinical research ...

RBC Capital analyst Sean Dodge maintained a Buy rating on Icon (ICLR – Research Report) yesterday and set a price target of $263.00. The ...

ICON Plc (ICLR), healthcare intelligence and clinical research company, on Tuesday reaffirmed its annual guidance. In addition, the ...

ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts ...